Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes In Stroke Care
Study, across 166 facilities in 17 states, finds AI-powered care coordination crucial for acute stroke management.
SAN FRANCISCO, CA. (February 8, 2023) Viz.ai, the leader in AI-powered disease detection and care coordination, and TeleSpecialists LLC, a physician-owned management service organization committed to providing exceptional emergent and non-emergent neurology and psychiatric patient care via telemedicine, announced new data presented today at the International Stroke Conference (ISC) from the VALIDATE (Validation of Artificial intelligence to LImit Delays in Acute stroke Treatment and Endovascular therapy) study. The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.
“In the world of stroke treatment, the saying ‘time is brain’ comes from the fact that when brain tissue is deprived of oxygenated blood, approximately two million neurons die every minute,” said Theresa Sevilis, DO, director of clinical research at TeleSpecialists and study co-author. “VALIDATE data show that use of the Viz platform resulted in a clinically important decrease in the time it took for large blood vessel occlusion recognition and contact with the interventional team, which in turn may translate to fewer neurons dying and, ultimately, better patient outcomes.”
The independent VALIDATE study analyzed data extracted from acute stroke consultations seen by TeleSpecialists’ neurologists in the emergency department across 166 facilities in 17 states. A total of 14,116 patients were included from two groups: those seen in hospitals using AI (n=8,557) and those seen in hospitals not using AI (n=5,559). The study found that the median door to neurointerventionalist notification time for AI was 50 minutes compared to the median door to neurointerventionalist notification time for non-AI at 89.5 minutes (p <0.001), a difference of 39.5 minutes. Importantly, the statistically significant (p<0.01) improvement in time to large clot recognition and contact with the neurointerventional team at Viz-enabled centers occurred regardless of whether the center did or did not have thrombectomy-capability.
“These data, which resulted from measuring the impact of our platform on patient care in the real world, reinforce results we’ve seen in previous studies that have typically involved a single center with a limited number of patients,” said Jayme Strauss, chief clinical officer, Viz.ai. “The first multi-center study involving a large number of patients, VALIDATE compared results from the same time period between hospitals that used the Viz.ai platform and those that did not have AI software, thus eliminating the potential confounding effect of changes in workflow that occur in hospitals over time. This tightly controlled scientific study clearly illustrates the tremendous impact of our technology.”
“The VALIDATE results demonstrate a time improvement in emergency stroke workflow between Viz-enabled and non-Viz-enabled centers that was statistically significant and highly clinically important,” said Thomas Devlin, MD, PhD, Professor of Neurology at the University of Tennessee Health Science Center, and co-author of the study. “The study design allowed for very careful and rigorous insight into exactly how powerful the Viz.ai platform is at expediting treatment for one of the most time-sensitive conditions in all of medicine”.
Viz.ai and TeleSpecialists announced a strategic partnership last year aimed at bringing AI-powered care coordination together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States.
For more information on the study results, visit the ISC website.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
About TeleSpecialists, LLC
TeleSpecialists is a leading national physician-owned provider of telemedicine solutions for quality-focused hospitals and healthcare systems that sets the standard for rapidly accessible remote neurology and psychiatry services, both emergent and non-emergent.